import { TimelineData } from "../timelineTypes";

export const ozempicTimelineData: TimelineData = {
  "2025": {
    firstHalf: [
      { date: "January 3", text: "The overall number of Ozempic lawsuit cases in the GLP-1 MDL increased to 1,331." },
      { date: "January 30", text: "A small study on nine patients using semaglutide or tirzepatide found that seven developed NAION, one experienced a retinal stroke, and one developed swelling in both optic nerves." },
      { date: "February 2", text: "A JAMA Network Open study reports that about 65% of people using GLP-1 drugs for weight loss stop within a year, mainly due to high costs, with side effects also playing a role." },
      { date: "February 4", text: "The total number of Ozempic lawsuit cases in the GLP-1 MDL increased to 1,443." },
      { date: "February 20", text: "An analysis of 37.1 million adults with type 2 diabetes across 14 databases found additional evidence linking semaglutide to NAION." },
      { date: "February 21", text: "Ozempic was removed from the FDA Drug Shortages List, effectively revoking permission for compounding pharmacies to produce semaglutide." },
      { date: "March 3", text: "The number of pending cases in the Ozempic MDL rose to 1,521." },
      { date: "March 6", text: "A study found a higher incidence of hair loss among patients taking semaglutide compared to another weight loss drug." },
      { date: "April 2", text: "The number of pending actions in the Ozempic MDL grew to 1,685." },
      { date: "April 7", text: "A BMC Medicine study found patients using semaglutide had a higher risk of vision impairment compared to other GLP-1 drugs." },
      { date: "April 16", text: "A North Carolina woman alleged Ozempic caused permanent vision loss due to NAION in a lawsuit filed in the MDL." },
      { date: "April 24", text: "A federal judge ruled that compounding pharmacies can no longer manufacture or sell their own versions of semaglutide." },
      { date: "April 25", text: "A 62-year-old Maryland man filed a lawsuit after developing NAION and losing vision in both eyes after taking Ozempic." },
      { date: "May 2", text: "The Ozempic MDL increased to 1,809 pending actions." },
      { date: "June 3", text: "The number of pending actions in the Ozempic MDL increased to 1,882." },
      { date: "June 17", text: "Twenty-one New Jersey plaintiffs filed lawsuits claiming permanent vision loss from GLP-1 drugs and requested multicounty litigation." }
    ],
    secondHalf: [
      { date: "July 2", text: "There were 1,997 pending actions in the Ozempic MDL." },
      { date: "August 1", text: "The MDL reached 2,190 active GLP-1 lawsuits, including Ozempic claims." },
      { date: "September 2", text: "The Ozempic MDL grew to 2,676 pending actions." },
      { date: "October 2", text: "The federal GLP-1 mass tort reached 2,809 pending actions." },
      { date: "November 3", text: "Over 100 new plaintiffs joined the MDL, raising the total to 2,914 cases." },
      { date: "December 3", text: "The total pending actions increased to 2,947." },
      { date: "December 17", text: "The JPML approved consolidation of vision loss lawsuits involving Ozempic and other GLP-1 drugs due to NAION." }
    ]
  },

  "2024": {
    firstHalf: [
      { date: "January 14", text: "Attorneys sought to consolidate Ozempic and Mounjaro lawsuits into a federal MDL." },
      { date: "February 4", text: "The Ozempic lawsuit was consolidated as MDL 3094 in the Eastern District of Pennsylvania under Judge Gene E. K. Pratter." },
      { date: "February 15", text: "Lawsuits alleged failure to warn about stomach paralysis and bowel obstruction, while gallbladder claims were excluded." },
      { date: "February 16", text: "The first status conference in the Ozempic MDL was scheduled for March 14, 2024." },
      { date: "February 24", text: "Novo Nordisk filed multiple lawsuits against pharmacies and sellers of knockoff semaglutide." },
      { date: "March 10", text: "Judge Pratter appointed leadership counsel, set discovery schedules, and ruled on admissible evidence." },
      { date: "March 21", text: "Many Ozempic lawsuits were expected to be filed in New Jersey state court in addition to federal court." },
      { date: "April 1", text: "Novo Nordisk sued pharmacies selling knockoff Ozempic as the FDA warned against compounded versions." },
      { date: "May 17", text: "Judge Pratter passed away, raising concerns about delays in the MDL." },
      { date: "June 6", text: "The Ozempic MDL was reassigned to Judge Karen S. Marston." }
    ],
    secondHalf: [
      { date: "July 1", text: "A JAMA Ophthalmology study linked semaglutide to NAION, increasing attention on vision loss lawsuits." }
    ]
  },

  "2023": {
    firstHalf: [],
    secondHalf: [
      { date: "August 1", text: "A 44-year-old woman filed one of the first Ozempic lawsuits alleging gastroparesis." },
      { date: "September 1", text: "Ozempic’s warning label was updated to include ileus and intestinal blockages." },
      { date: "November 1", text: "Novo Nordisk filed a motion to dismiss the Bjorklund lawsuit." },
      { date: "December 1", text: "A judge denied Novo Nordisk’s motion to dismiss, allowing failure-to-warn claims to proceed." },
      { date: "December 31", text: "A total of 6,487 cases and 89 deaths were reported." }
    ]
  }
};
